Encompass Health Research and Development Expenses 2010-2024 | EHC

Encompass Health annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Encompass Health research and development expenses for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Encompass Health research and development expenses for the twelve months ending September 30, 2024 were $0M, a NAN% increase year-over-year.
  • Encompass Health annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • Encompass Health annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
  • Encompass Health annual research and development expenses for 2021 were $0B, a NAN% decline from 2020.
Encompass Health Annual Research and Development Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Encompass Health Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $9.984B $4.801B
Encompass Health Corporation is a provider of integrated healthcare services. It offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. The company delivers high-quality, cost-effective, integrated care in the healthcare space. It provides a continuum of facility-based and home-based post-acute services for its patients and their families, which will gain more prevalence as coordinated care and integrated delivery payment models, such as accountable care organizations and bundled payment arrangements. The company operates through two segments: Inpatient Rehabilitation as well as Home Health and Hospice business.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $19.458B 11.77
Quest Diagnostics (DGX) United States $17.988B 18.23
DaVita (DVA) United States $12.872B 16.65
Chemed (CHE) United States $8.238B 25.32
Elanco Animal Health (ELAN) United States $6.580B 15.66
RadNet (RDNT) United States $5.911B 130.90
Option Care Health (OPCH) United States $3.713B 17.60
Amedisys (AMED) United States $2.948B 20.98
LifeStance Health (LFST) United States $2.770B 0.00
Astrana Health (ASTH) United States $2.302B 31.49
Addus HomeCare (ADUS) United States $2.180B 25.57
U.S Physical Therapy (USPH) United States $1.368B 35.96
Aveanna Healthcare Holdings (AVAH) United States $1.121B 0.00
Pennant (PNTG) United States $1.093B 44.18
Atai Life Sciences (ATAI) Germany $0.290B 0.00
Daxor (DXR) United States $0.043B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.015B 0.00
Psychemedics (PMD) United States $0.014B 0.00
ATI Physical Therapy (ATIP) United States $0.008B 0.00
Ontrak (OTRK) United States $0.008B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00